Dyne Therapeutics, Inc.DYNNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+39.7%
5Y CAGR+51.7%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+39.7%/yr
vs +144.4%/yr prior
5Y CAGR
+51.7%/yr
Recent deceleration
Acceleration
-104.7pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
8x
Strong expansion
Streak
7 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $466.13M | +36.4% |
| 2024 | $341.64M | +42.5% |
| 2023 | $239.70M | +40.2% |
| 2022 | $170.96M | +14.0% |
| 2021 | $150.03M | +158.9% |
| 2020 | $57.95M | +319.1% |
| 2019 | $13.83M | +188.3% |
| 2018 | $4.79M | -97.5% |
| 2017 | $189.00M | +17.4% |
| 2016 | $161.00M | - |